Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Feb;190:118-22.
doi: 10.1192/bjp.bp.106.022707.

Omega-3 Fatty Acid Supplementation in Patients With Recurrent Self-Harm. Single-centre Double-Blind Randomised Controlled Trial

Affiliations
Randomized Controlled Trial

Omega-3 Fatty Acid Supplementation in Patients With Recurrent Self-Harm. Single-centre Double-Blind Randomised Controlled Trial

Brian Hallahan et al. Br J Psychiatry. .

Abstract

Background: Trials have demonstrated benefits of long-chain omega-3 essential fatty acid (n-3 EFA) supplementation in a variety of psychiatric disorders.

Aims: To assess the efficacy of n-3 EFAs in improving psychological well-being in patients with recurrent self-harm.

Method: Patients (n=49) presenting after an act of repeated self-harm were randomised to receive 1.2 g eicosapentaenoic acid plus 0.9 g decosahexaenoic acid (n=22) or placebo (n=27) for 12 weeks in addition to standard psychiatric care. Six psychological domains were measured at baseline and end point.

Results: At 12 weeks, the n-3 EFA group had significantly greater improvements in scores for depression, suicidality and daily stresses. Scores for impulsivity, aggression and hostility did not differ.

Conclusions: Supplementation achieved substantial reductions in surrogate markers of suicidal behaviour and improvements in well-being. Larger studies are warranted to determine if insufficient dietary intake of n-3 EFAs is a reversible risk factor for self-harm.

Comment in

Similar articles

See all similar articles

Cited by 35 articles

See all "Cited by" articles

Publication types

Substances

Feedback